Illumina Inc. has announced the release of its novel 5-base solution, a significant advancement in multiomic analysis that enables researchers to simultaneously detect genomic variants and DNA methylation from a single sample. This new technology streamlines workflows and reduces costs, potentially accelerating research in areas such as rare disease, cancer, and precision medicine. The scientific research results demonstrating the power of the 5-base genome for resolving rare disease cases will be presented by Dr. Bekim Sadikovic at the American Society of Human Genetics (ASHG) annual meeting on October 15.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA98351) on October 15, 2025, and is solely responsible for the information contained therein.